Matthew Buten - Net Worth and Insider Trading

Matthew Buten Net Worth

The estimated net worth of Matthew Buten is at least $8 Million dollars as of 2024-05-05. Matthew Buten is the CFO of Biohaven Ltd and owns about 189,380 shares of Biohaven Ltd (BHVN) stock worth over $8 Million. Details can be seen in Matthew Buten's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Matthew Buten has not made any transactions after 2023-10-05 and currently still holds the listed stock(s).

Transaction Summary of Matthew Buten

To

Matthew Buten Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Matthew Buten owns 2 companies in total, including Biohaven Pharmaceutical Holding Co Ltd (BHVN) , and Biohaven Ltd (BHVN) .

Click here to see the complete history of Matthew Buten’s form 4 insider trades.

Insider Ownership Summary of Matthew Buten

Ticker Comapny Transaction Date Type of Owner
BHVN Biohaven Pharmaceutical Holding Co Ltd 2021-12-08 Officer
BHVN Biohaven Ltd 2023-10-05 Chief Financial Officer

Matthew Buten Latest Holdings Summary

Matthew Buten currently owns a total of 1 stock. Matthew Buten owns 189,380 shares of Biohaven Ltd (BHVN) as of October 5, 2023, with a value of $8 Million.

Latest Holdings of Matthew Buten

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BHVN Biohaven Ltd 2023-10-05 189,380 40.69 7,705,872

Holding Weightings of Matthew Buten


Matthew Buten Form 4 Trading Tracker

According to the SEC Form 4 filings, Matthew Buten has made a total of 2 transactions in Biohaven Ltd (BHVN) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Biohaven Ltd is the acquisition of 22,727 shares on October 5, 2023, which cost Matthew Buten around $499,994.

Insider Trading History of Matthew Buten

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Matthew Buten Trading Performance

GuruFocus tracks the stock performance after each of Matthew Buten's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Matthew Buten is 54.59%. GuruFocus also compares Matthew Buten's trading performance to market benchmark return within the same time period. The performance of stocks bought by Matthew Buten within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Matthew Buten's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Matthew Buten

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 18.81
Relative Return to S&P 500(%) 15.47

Matthew Buten Ownership Network

Ownership Network List of Matthew Buten

No Data

Ownership Network Relation of Matthew Buten


Matthew Buten Owned Company Details

What does Biohaven Pharmaceutical Holding Co Ltd do?

Who are the key executives at Biohaven Pharmaceutical Holding Co Ltd?

Matthew Buten is the Officer of Biohaven Pharmaceutical Holding Co Ltd. Other key executives at Biohaven Pharmaceutical Holding Co Ltd include VP & Chief Accounting Officer George C. Clark , Chief Medical Officer Elyse Stock , and Chief Financial Officer James Engelhart .

Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Biohaven Pharmaceutical Holding Co Ltd (BHVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Biohaven Pharmaceutical Holding Co Ltd Insider Transactions

No Available Data

Matthew Buten Mailing Address

Above is the net worth, insider trading, and ownership report for Matthew Buten. You might contact Matthew Buten via mailing address: 215 Church Street, New Haven Ct 06510.

Discussions on Matthew Buten

No discussions yet.